Halozyme Therapeutics, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 89   

Articles published

HALO 16.78 +0.18 (1.08%)
price chart
Here's Why Halozyme Therapeutics, Inc. Is Soaring Today
Shares of Halozyme Therapeutics (NASDAQ:HALO), a small-cap biotech focused on creating products that help other drugs work more effectively, rose by 16% as of 10:45 a.m.
Strength Seen in Halozyme Therapeutics (HALO): Stock Soars 21.2% September ...  Zacks.com
Halozyme Therapeutics (HALO) Soars On Raised Revenue Forecast  Economic Calendar
Halozyme Therapeutics: Updates To Thesis
Adoption and utilization of its ENHANZE technology continues to drive growth, highlighted by the recent deal signed with Bristol-Myers Squibb.
Can Halozyme (HALO) Run Higher on Strong Earnings Estimate Revisions?  Nasdaq
Digging Up the Facts on Halozyme Therapeutics, Inc. (HALO)
Halozyme Therapeutics, Inc. (HALO) is an interesting player in the Healthcare space, with a focus on Biotechnology. The stock has been active on the tape, currently trading at $16.72, up from yesterday's close by 2.89%.
Halozyme Therapeutics Inc. (HALO) Moves Lower on Volume Spike for September 19  Equities.com
Hot Stock Update: Halozyme Therapeutics, Inc. (HALO)  FactsReporter
Why Halozyme Therapeutics, Tenet Healthcare, and AMC Entertainment Holdings ...
Shares of Halozyme Therapeutics jumped 21% after the biotechnology company announced two major collaborations with larger peers in the healthcare space.
Halozyme to license drug delivery tech to Roche, Bristol-Myers  Reuters
Halozyme Licenses New Enhanze Target For $30 Million Upfront Payment, Future ...  PR Newswire (press release)
Halozyme Therapeutics Presents at 2017 Wells Fargo Healthcare Conference ...
It's my pleasure to welcome on behalf of Wells Fargo, Halozyme and the CEO, Helen Torley. For those of you that don't know the Halozyme story, the company has several pillars of value drivers and ENHANZE platform to facilitate delivery of large ...
Halozyme's stock soars after Bristol-Myers license deal
Shares of Halozyme Therapeutics Inc. HALO, -0.08% rocketed 13% in premarket trade Thursday, after the biotechnology company announced a license agreement with Bristol-Myers Squibb Co.
Dissecting the Investment Cases for Halozyme Therapeutics, Inc. (HALO) and ...
Halozyme Therapeutics, Inc. (NASDAQ:HALO) and Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) are both Healthcare companies that recently hit new low.
Technical Insights on Biotech Stocks -- Grifols, Halozyme Therapeutics ...
Shares in San Diego, California headquartered Halozyme Therapeutics Inc. ended at $13.01, up 2.12% from the last trading session.
Analysts Poring Over the Numbers on Halozyme Therapeutics, Inc. (NASDAQ:HALO)
Investors paying close attention to the daily ebbs and flows of the stock market may be trying to guess which way momentum will swing into the next couple of months.
Let's Get Complex With Sigma Designs, Inc. (SIGM) And Halozyme Therapeutics ...
Sigma Designs, Inc. (NASDAQ:SIGM) traded at an unexpectedly low level on 09/21/2017 when the stock experienced a -2.44% loss to a closing price of $6.